On April 2, the Trump administration signed a proclamation invoking Section 232 of the Trade Expansion Act to impose 100 percent tariffs on patented pharmaceutical imports and their active ingredients. The announcement was framed as a national security measure: approximately 53 percent of patented drugs sold in the United States are produced abroad, and only 15 percent of the active pharmaceutical ingredients used in the most innovative medicines are made domestically. The administration called this a threat to the supply chain. The tariffs, it argued, would incentivize onshoring.
The structure of the proclamation is where the policy meets patients. Generic drugs are exempt. Orphan drugs — treatments for rare diseases affecting small patient populations — are exempt. Biosimilars are exempt. What is not exempt is the category of drugs that carries the most weight for the most serious conditions: patented branded pharmaceuticals, which include the majority of cancer treatments, autoimmune therapies, and specialty biologics currently in clinical use.
The timing is tiered. For seventeen named large pharmaceutical companies, the tariffs take effect July 31, 2026. For all other importers, the effective date is September 29. Companies that have signed Most Favored Nation pricing agreements with the Department of Health and Human Services pay no tariff at all until January 2029. Companies that commit to building domestic manufacturing capacity face a reduced rate of 20 percent, rising to 100 percent in April 2030 if onshoring is not complete.
The practical consequence for patients is not uniform. For treatments sourced from Japan, EU member states, South Korea, Switzerland, and the United Kingdom, the rate is 15 percent rather than 100. For treatments sourced from countries without trade deals, the effective rate varies depending on what share of those imports are already generic and therefore exempt. A Health Affairs analysis estimated that a 100 percent worldwide tariff on active pharmaceutical ingredients used in domestic generic production could raise average finished drug prices by roughly 30 percent under baseline assumptions. The administration has argued that the MFN pricing mechanism, running in parallel, will offset these increases. Critics note that the MFN process moves on a different timeline than the tariff implementation.
The deeper tension in the policy is between two goals that pull in opposite directions. Tariffs raise the cost of imports, which is meant to make domestic production more competitive. But the drugs most dependent on foreign manufacturing are often treatments for conditions where there is no domestic alternative to move toward — rare gastrointestinal tumors, cutaneous lymphomas, certain autoimmune diseases — and the manufacturers making those treatments are small enough that the economics of building American factories do not work at any plausible tariff rate. The proclamation exempts orphan drugs, but the line between an orphan drug and a specialty oncology treatment is not always clear in clinical practice.
The question that the tariff does not answer is the one that patients will be asking by August: which of my medications is covered by this, and what happens if my insurer adjusts its formulary in response to the cost increase. The administration has said it will release further guidance. July 31 is eleven weeks away.
American Life is independent analysis.
